|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2018 - Nov 19, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Feb. 15, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming ...
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com ANAHEIM, Calif. , Feb. 15, 2019 ...
The Uptick Newswire Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc Brady Granier and CFO Lourdes Felix talked with Stock Day’s Everett Jolly. At the start of the interview Jolly asked about the National Institute on Drug Abuse (NIDA) grant and what it would mean to the company.
BICXD) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today a reverse stock split of its shares of common stock at a ratio of 1-for-100. The reverse split took effect at the open of business Tuesday, January 22, 2019.
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has been awarded a 2-year grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number UG3DA047925 for the development of BICX102, the Company’s single administration, multi-month sustained release naltrexone implant for the treatment of opioid use disorder. The Company is seeking FDA approval for BICX102.
SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that a new audio interview with the Company is now available. Brady Granier called in to SmallCapVoice.com, Inc. to discuss the progress the Company has made in several key areas, the operational outlook for 2019, the launch of a new weight loss program and more. BioCorRx, Inc. issued a third quarter business update in November outlining where the Company stands with NIDA on their grant application process.